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FBXW7-mediated ERK3 degradation regulates the proliferation
of lung cancer cells
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Extracellular signal-regulated kinase 3 (ERK3) is an atypical member of the mitogen-activated protein kinase (MAPK) family,
members of which play essential roles in diverse cellular processes during carcinogenesis, including cell proliferation,
differentiation, migration, and invasion. Unlike other MAPKs, ERK3 is an unstable protein with a short half-life. Although
deubiquitination of ERK3 has been suggested to regulate the activity, its ubiquitination has not been described in the literature.
Here, we report that FBXW7 (F-box and WD repeat domain-containing 7) acts as a ubiquitination E3 ligase for ERK3. Mammalian
two-hybrid assay and immunoprecipitation results demonstrated that ERK3 is a novel binding partner of FBXW7. Furthermore,
complex formation between ERK3 and the S-phase kinase-associated protein 1 (SKP1)-cullin 1-F-box protein (SCF) E3 ligase resulted
in the destabilization of ERK3 via a ubiquitination-mediated proteasomal degradation pathway, and FBXW7 depletion restored ERK3
protein levels by inhibiting this ubiquitination. The interaction between ERK3 and FBXW7 was driven by binding between the C34D
of ERK3, especially at Thr417 and Thr421, and the WD40 domain of FBXW7. A double mutant of ERK3 (Thr417 and Thr421 to alanine)
abrogated FBXW7-mediated ubiquitination. Importantly, ERK3 knockdown inhibited the proliferation of lung cancer cells by
regulating the G1/S-phase transition of the cell cycle. These results show that FBXW7-mediated ERK3 destabilization suppresses
lung cancer cell proliferation in vitro.
Experimental & Molecular Medicine (2022) 54:35–46; https://doi.org/10.1038/s12276-021-00721-9

INTRODUCTION
Extracellular signal-regulated kinase 3 (ERK3) family members are
atypical MAPKs and include ERK3, ERK4, ERK7, and Nemo-like
kinase (NLK)1. The biological activities of these members are
mainly regulated by phosphorylation at the activation loop motif
Thr-Xaa-Tyr that is catalyzed by a family of dual-speciﬁcity protein
kinases2 and by subcellular localization3,4. A structural difference
within the highly conserved activation loop motif sequence SerGlu-Gly (rather than Thr-Xaa-Tyr) is responsible for the functional
characteristics of ERK3 that distinguish it from other MAPKs5.
Strikingly, unlike other MAPK members, ERK3 is an unstable
protein with a half-life of <30 min5. Thus, it appears likely that
ERK3 expression reﬂects its activity. Turnover experiments using
deletion and truncation mutants of ERK3 have indicated that
neither kinase activity nor the C-terminal extension of ERK3 is
required for its high turnover5. ERK3 harbors two degradation
domains in its N-terminal lobe that are both necessary and
sufﬁcient to target ERK3 for ubiquitination and degradation via the
proteasomal degradation pathway5,6. However, the domain(s) of
ERK3 that interact with E3 ubiquitin ligase(s) and the identities of
the responsible E3 ligase(s) have not been elucidated.

The roles of ERK3 in cancer are controversial. Previous reports
have demonstrated that ERK3 overexpression in NIH3T3 cells
suppresses BrdU incorporation7 and that the expression of
stabilized forms of ERK3 causes G1 cell cycle arrest in NIH3T3
cells5. These results suggest that ERK3 inhibits cell proliferation.
However, others have reported that ERK3 expression is upregulated in several human cancer microarrays databases8–11 and that
ERK3 is upregulated in human lung cancer tissues12. However, in
an in vitro cell culture system, ERK3 overexpression slightly
suppressed HeLa cell proliferation13, and in lung cancer cells,
ectopic ERK3 expression signiﬁcantly induced cell proliferation14.
However, the physiological roles of ERK3 have been studied in the
contexts of cell migration and invasion. Recent reports have
indicated that ERK3 is required for the maintenance of epithelial
architecture via regulation of epithelial morphogenesis and
differentiation15. In this process, ERK3 plays an essential role in
IL-8 production and chemotaxis of leukocytes by modulating cJun/AP-1 activity16. Moreover, β-adrenergic stimulation stabilizes
the ERK3 protein, resulting in an increase in ERK3/MK5 complex
formation17. This process transduces activation of FOXO1 and
promotes the expression of the major lipolytic enzyme ATGL17.
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Moreover, since PKC-mediated ERK3 serine phosphorylation and
microtubule-associated protein 2 (MAP2) association are involved
in glucose-induced insulin secretion and since ERK3 expression is
modulated by prolactin in isolated rat pancreatic islets18,
ERK3 seems to be involved in insulin secretion19. However, the
detailed molecular action mechanisms of ERK3, physiological
conditions for ERK3 activity regulation, and downstream target
proteins, including transcription factors, are not well understood.
Substrate selectivity for F-box-mediated ubiquitination is
mediated by two major functional domains: the F-box motif,
which directly binds to the adaptor protein SKP1 and recruits the
F-box protein into the S-phase kinase-associated protein 1 (SKP1)cullin 1-F-box protein (SCF) complex, and various carboxylterminal domains, which bind to speciﬁc substrates20. FBXW7
has three isotypes, FBXW7α, FBXW7β, and FBXW7γ, that exhibit
different subcellular localizations (i.e., nucleoplasm, cytoplasm,
and nucleoli, respectively)21. Thus, the isotype speciﬁcities of
FBXW7 for substrates are dependent on the subcellular localization of FBXW7, its substrates, and cellular signaling.
FBXW7 substrates include cyclin E, MYC, JUN, MOTCH, myeloid
cell leukemia 1 (MCL1), SREBP, mTOR, KLFs, CCAAT/enhancerbinding proteins (C/EBPs), and the mediator complex components
MED13 and MED13L, which all contain a conserved phosphorylated degron sequence, (Leu)-pThe/pSer-Pro-Pro-X-pSer/pThr/Glu/
Asp22,23. These observations suggest that FBXW7 plays an
essential role in diverse cellular processes depending on different
cellular contexts in cancer cells.
In this study, we found that ERK3 is a binding partner of FBXW7
and that the interaction between the two proteins results in ERK3
ubiquitination and destabilization. Furthermore, this interaction was
found to involve binding between the C34 domain (C34D) of ERK3
and the WD40 domain of FBXW7. In addition, mutations of Thr417
and Thr421 in ERK3 to alanine suppressed ERK3 ubiquitination, and
ERK3 knockdown suppressed lung cancer cell proliferation. These
observations suggest that the FBXW7-ERK3 degradation pathway
plays an important role in cancer cell proliferation.
MATERIALS AND METHODS
The general methodologies, including transfection, Western blotting, sitedirected mutagenesis, real-time polymerase chain reaction, and focus
formation assay, are described in detail in the Supplemental Materials.
Material sharing can be requested by contacting the corresponding author
(YY Cho, yongyeon@catholic.ac.kr).

Reagents
Reagents for molecular and cellular biological studies, such as dimethyl
sulfoxide (Cat #: D2650), cycloheximide (CHX; Cat #: 01810), and MG132
(Cat #: C2211), were purchased from Sigma-Aldrich (Sigma-Aldrich Korea,
Gangnam, Seoul, Korea). TRIzol reagent (Cat #: 15596026) for RNA isolation
was purchased from Thermo Fisher Scientiﬁc (Grand Island, NY, USA).
Antibodies including anti-cyclin E (Cat #: sc-247), anti-Myc (Cat #: sc-40),
anti-cullin 1 (Cat #: sc-17775), and anti-β-actin (Cat #: sc-47778) used for
Western blotting and/or immunoprecipitation (IP) were obtained from
Santa Cruz Biotechnology (Dallas, Texas, USA). An anti-FBXW7 antibody
(Cat #: A301-721A) was obtained from Bethyl Laboratories, Inc. (Montgomery, Texas, USA). An anti-ERK3 antibody (Cat #: 4047) and an anti-HAHRP antibody (Cat #: M180-7) were obtained from Cell Signaling
Technology (Koram Biotech Corp., Gangnam, Seoul) and MBL International
(Woburn, MA, USA), respectively. Protein G Sepharose beads (Cat #: 170618-02), which were used to pull down antibodies, were purchased from
GE Healthcare (Chicago, IL, USA). A CellTiter 96® AQueous One Solution Cell
Proliferation Assay (Cat #: G3580) and crystal violet (Cat #: C1035) were
purchased from Promega (Woods Hollow Road, Fitchburg, USA) and
BIOSESANG (Sungnam, Gyeonggi, Korea), respectively.

(FBS, Cat #: 35-015-CV, Corning Korea) containing 100 U penicillin and
100 µg/mL streptomycin (Cat #: 15070063, Thermo Fisher Scientiﬁc, Grand
Island, NY, USA). A549 and H1299 lung cancer cells were cultured in RPMI1640 (Cat #: 10-040-CV, Corning Korea) supplemented with 10% FBS
containing 10 mM glutamine (Cat #: 25030081 Thermo Fisher Scientiﬁc),
100 U penicillin, and 100 µg/mL streptomycin (Cat #: 15070063, Thermo
Fisher Scientiﬁc). FBXW7+/+ and FBXW7−/− HCT116 cells (HCT116FBXW7+/+
and HCT116FBXW7−/− cells) were kindly donated by Dr. Bert Vogelstein at
the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University24. All cell lines were maintained at 37 °C in a 5% CO2 incubator.

Expression vectors
Mammalian two-hybrid vectors, pACT (VP16 fusion) and pBIND (Gal4
fusion), were purchased from Promega, and Myc- and HA-fusion vectors
were purchased from TAKARA Bio Inc. (Kusatsu, Shiga, Japan). A His/Xpress
fusion vector was purchased from Thermo Fisher Scientiﬁc, and a Flag-tag
expression vector was purchased from Addgene (Watertown, MA, USA).
Fusion expression vectors were constructed by inserting DNA fragments
into the multicloning sites of pACT, pBIND, pCMV-Myc, pCMV-Flag, or
pCMV-HA as indicated. We used pCDH-CMV-MCS-EF1-puro (Addgene) to
overexpress FBXW7, ERK3-wt, and ERK3-mtPDM2 (designated pCDHFBXW7, ERK3-wt, and ERK3-mtPDM2, respectively). All expression vectors
were conﬁrmed by DNA sequencing before use.

Cell proliferation assay

To measure cell proliferation, A549 (1.5 × 103 cells/well) or H1299 (2.0 × 103
cells/well) lung cancer cells were seeded into 96‐well plates in 100 μL of
cell culture medium and incubated for 2 h at 37 °C in a 5% CO2 incubator.
At baseline, the absorbance was measured at 492 and 690 nm (to account
for background debris, ﬁngerprints, and other nonspeciﬁc absorbances)
using MTS (3‐(4,5‐dimethylthiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐
sulfophenyl)‐2H‐tetrazolium)‐based CellTiter 96 Aqueous One Solution
according to the manufacturer’s instructions (Promega, Madison, WI).
Brieﬂy, 20 μL of MTS solution was added per well, and the cells were
incubated for 1 h at 37 °C in a 5% CO2 incubator. The reaction was stopped
by adding 25 μL of 10% sodium dodecyl sulfate (SDS) solution to each well,
and absorbances were measured immediately at 492 and 690 nm using an
xMark™ Microplate Absorbance Spectrophotometer (Bio-Rad Laboratories,
Hercules, CA, USA). Cell proliferation was evaluated by comparing sample
absorbances measured over 96 h at 24 h intervals.

Mammalian-two hybrid assay
Promega Checkmate Mammalian Two-Hybrid System protocols were used
for the mammalian two-hybrid (M2H) assays. In brief, HEK293T cells were
maintained in 10% FBS–DMEM, seeded into 48-well plates (2 × 104 cells/
well), and incubated with 10% FBS–DMEM for 18 h before transfection.
DNAs, pACT kinases (including ERK3 and pBIND-FBXW7), and pG5luciferase were combined at a molar ratio of 1:1:1. The total amount of
DNA did not exceed 100 ng per well. Transfection was performed using
H4000 (Engreen Biosystem Ltd., Beiyuan, Beijing China) according to the
manufacturer’s instructions. For luciferase assays, cells were disrupted by
adding passive lysis buffer (Cat #: E1941, Promega) and incubating for
30 min at room temperature with gentle shaking. Luciferase activities were
measured automatically using a Dual-Luciferase® Reporter Assay (Cat #:
E1910, Promega), and data were obtained using a Victor X3 plate reader
(PerkinElmer Korea, Guro, Seoul). The relative luciferase activities were
determined using pG5-luciferase basal controls and normalized against
Renilla luciferase activity. The pBIND vector was included as an internal
control.

Gene knockdown and ectopic expression
HEK293T cells were used for packaging of lentiviral or retroviral expression
vectors to produce viral particles. The viral particles were then used to
infect various cell lines. In brief, media containing secreted viruses were
collected twice at 24 and 48 h after transfection and then ﬁltered with
0.45 μm acetate syringe ﬁlters. Various cell lines were infected with the
viruses in the presence of 1 μg/ml polybrene (Sigma-Aldrich Korea) and
cultured for 48 h. Cells were selected using puromycin (5 μg/ml) for 3 days.

Cell culture

HEK293T cells, HCT116FBXW7+/+ cells, and HCT116FBXW7−/− cells were
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM, Cat #: 10-013-CV,
Corning Korea, Seoul, Korea) supplemented with 10% fetal bovine serum

Immunoprecipitation
Protein–protein interactions were investigated by IP and Western blotting.
Antibodies (2 µg) in 700 µl of cell lysis buffer were added to cell lysates
Experimental & Molecular Medicine (2022) 54:35 – 46
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(300–400 µg) and hybridized with gentle inversion overnight at 4 °C. The
lysates were then added to 30 µl of a 50% slurry of protein G Sepharose
beads and incubated for 2 h at 4 °C. The interacting proteins were obtained
by washing the beads with wash buffer (20 mM Tris at pH 8.0, 100 mM
NaCl, 1 mM EDTA, and 0.5% NP-40) three times. The proteins were then
resolved by SDS-PAGE and visualized by Western blotting using indicated
antibodies.

De novo ubiquitination assay
To quantify ubiquitination in cell culture, we cotransfected HEK293T cells
with HA-ubiquitin or His-ubiquitin and Myc-ERK3 with or without FBXW7 as
indicated. Cell lysates (300–400 μg) were immunoprecipitated using
speciﬁc antibodies, and ubiquitinated ERK3 was detected using HA-tagspeciﬁc antibodies. Simultaneously, immunoprecipitated ERK3 levels were
detected using endogenous ERK3 or Tag-speciﬁc antibodies. Ubiquitinated
ERK3 was quantiﬁed by measuring the intensities of whole smear bands,
and relative ERK3 ubiquitination values were obtained by equalizing the
intensities of immunoprecipitated endogenous ERK3 or Tag-fusion ERK3.

In vitro ubiquitination assay
The substrate proteins ERK3-wt and ERK3-mtPDM2 were prepared via
coexpression of HA-GSK3β and Myc-Ab-conjugated bead pulldown in
HCT116FBXW7−/− cells. The beads were washed ﬁve times in NETN buffer
(20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.5% NP-40) and
incubated with EBC solution (50 mM Tris-HCl [pH 8.0], 120 mM NaCl, 0.5%
NP-40) for hybridization with immune-puriﬁed Flag-FBXW7. SCFFBXW7
complexes were prepared with an anti-Flag M2 afﬁnity gel (Cat #:2220,
Sigma-Aldrich Korea) and by elution with 3x Flag- peptide (Cat #: F4799,
Sigma–Aldrich Korea) using the cell lysate from transiently Myc-cullin 1-,
Myc-Rbx1-, and Flag-FBXW7-coexpressing HEK293T cells. For the in vitro
ubiquitination assay, substrates (Myc-Ab-ERK3-wt and Myc-Ab-ERK3mtPDM2) and SCFFBXW7 complexes were mixed together with the
components of a ubiquitination kit (Cat #: BML-UW9920, ENZO Life
Sciences, New York, NY, USA), and the assay was performed according to
the manufacturer’s instructions. The ubiquitination of the ERK3-wt and
ERK3-mtPDM2 proteins was visualized by Western blotting using an ERK3
antibody and an HRP-conjugated secondary antibody. The input was used
to conﬁrm the utilized protein amount for the in vitro ubiquitination assay
by Western blotting.

Cell synchronization and cell cycle release
A549 cells were used for cell cycle regulation assays, which involved HUinduced synchronization and subsequent release from the G1/S-phase
using CDH-mock-, CDH-ERK3-wt-, and CDH-ERK3-mtPDM2-expressing cells.
Brieﬂy, the cells were treated with HU (2 mM) for 48 h, released by rinsing
with 1× phosphate-buffered saline twice and refed with complete medium
for the indicated times (referred to as “release times”). The cells were then
trypsinized, ﬁxed with ice-cold ethanol, and treated with RNase A (100 μg/
mL) followed by propidium iodide (20 μg/mL). The cell cycle distributions
were analyzed by ﬂow cytometry (BD FACSCalibur™ ﬂow cytometer,
Franklin Lakes, NJ, USA).

RESULTS
ERK3 is a novel binding partner of FBXW7
To identify the binding partner of FBXW7, Gal4-FBXW7 in the
pBIND vector was used as a bait to screen for novel binding sites
using MAPK kinases, which were recombined into the pACT
expression vector. Mammalian two-hybrid assay results showed
that FBXW7-ERK3 binding was approximately 4.5-fold greater than
the binding between FBXW7 and negative control (vs. pBINDFBXW7/pACT-mock) (Fig. 1a). The interaction between ERK3 and
FBXW7 was conﬁrmed by IP using HEK293T cell lysates ectopically
expressing Myc-FBXW7 and Gal4-ERK3 (Fig. 1b). Since FBXW7 is a
member of the cullin 1 SCF complex family25, we ﬁrst conﬁrmed
the binding of ERK3 to cullin 1 by IP. The results demonstrated
that ERK3 is bound to cullin 1 (Fig. 1c). We further evaluated
speciﬁc binding between ERK3 and isotype(s) of cullin family
members (i.e., cullin 1, 2, 3, 4A, 4B, and 7) and observed that ERK3
coimmunoprecipitated with cullin 1 and 4B (Fig. 1d). Speciﬁc
endogenous ERK3 binding with FBXW subfamily members,
Experimental & Molecular Medicine (2022) 54:35 – 46

including βTrCP1, βTrCP2, FBXW2, FBXW4, FBXW5, FBXW7, and
FBXW8, was evaluated using ex vivo Flag-tag pulldown assays. We
found that immunoprecipitated ERK3 was detected only in the
presence of FBXW7 (Fig. 1e). Using expression constructs, we
further found that ERK3 interacted with FBXW7 and FBXO 4, 6, and
17 (Fig. 1f). These results suggest that ERK3 may also interact with
other F-box subfamily members. Since our laboratory possessed
many constructs that allowed a detailed investigation of the
molecular mechanisms of FBXW725, we focused on the interaction
between FBXW7 and ERK3. Our results showed that the ERK3/
FBXW7 interaction is speciﬁc for the FBXW subfamily of F-box
proteins.
FBXW7 destabilizes ERK3 by ubiquitination
After ﬁnding that ERK3 was a novel binding partner of FBXW7
(Fig. 1a–c), we examined whether ERK3 protein content was
regulated via proteasomal degradation. To examine this hypothesis, we treated H226 and H1299 lung cancer cells with MG132, a
proteasomal degradation inhibitor. The results demonstrated that
ERK3 protein levels were markedly higher in MG132-treated cells
than in nontreated controls (Fig. 2a). As we have reported
previously25, MG132 treatment restored cyclin E protein levels,
indicating that ERK3 protein levels were regulated by the
proteasomal degradation pathway (Fig. 2a). Notably, increasing
the ectopic expression of FBXW7 dose-dependently reduced ERK3
protein levels (Fig. 2b). Moreover, cullin 1 knockdown in A549 lung
cancer cells elevated ERK3 protein levels (Fig. 2c). When cullin
1-knockdown A549 lung cancer cells were treated with cycloheximide (CHX), ERK3 protein levels were sustained. On the other
hand, sh-mock A549 cells showed gradual, time-dependent
reductions in ERK3 protein levels after CHX treatment (Supplementary Fig. 1a), which indicated that FBXW7 regulates ERK3
protein levels via a proteasomal degradation pathway. This result
was further supported by higher ERK3 protein levels in
HCT116FBXW7−/− cells than in HCT116FBXW7+/+ cells (Fig. 2d, upper
panels). Since ERK3 mRNA levels were similar in these cells (Fig. 2d,
bottom graph), we concluded that the elevated ERK3 protein
levels were caused by enhanced protein stability and not by gene
expression. Notably, cycloheximide (CHX) treatment demonstrated that the degradation rate of ERK3 proteins in
HCT116FBXW7−/− cells was slower than that in HCT116FBXW7+/+
cells (Fig. 2e). As expected, coexpression of ERK3 and FBXW7
dramatically increased ERK3 ubiquitination compared to that
achieved with ERK3 alone (Fig. 2f). Furthermore, ERK3 ubiquitination was markedly abolished in HCT116FBXW7−/− cells (Fig. 2g). In
contrast to FBXW7 overexpression, FBXW7 knockdown in A549
cells (Supplementary Fig. 1b) increased not only the total protein
level of ERK3 but also ERK3 turnover after CHX treatment (Fig. 2h).
The increased levels of cyclin E induced by sh-FBXW7 provided
evidence that the experiment was suitable (Fig. 2h). Notably, the
reintroduction of FBXW7 overexpression plasmids into FBXW7knockdown cells resulted in dramatic reductions in ERK3 levels
(Fig. 2i). In contrast, the reduced ERK3 protein stability caused by
FBXW7 overexpression compared to that in the mock control
group was attenuated by knockdown of FBXW7 in a timedependent manner (Fig. 2j). However, FBXW7 knockdown resulted
in a gradual degradation trend, indicating the presence of other
ERK3 ubiquitination enzymes. Although Figs. 1d, f and 2j suggest
that other F-box proteins may be involved in the regulation of
ERK3, the results overall indicate that FBXW7-mediated ERK3
ubiquitination regulates ERK3 protein stability via the proteasomal
degradation pathway.
The C34D of ERK3 interacts with the WD40 domain of FBXW7
To identify the domain of ERK3 responsible for its interaction with
FBXW7, we constructed serial deletion mutants of ERK3 harboring
amino acids 1–721 (Myc-ERK3-1–721), 1–481 (Myc-ERK3-1-481), or
1–340 (Myc-ERK3-1-340) (Supplementary Fig. 2a). IP experiments
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Fig. 1 ERK3 is a novel binding partner of FBXW7. a Interaction screening of FBXW7 and kinases by mammalian two-hybrid assay. The
interaction strengths between FBXW7 and each of the indicated kinases were assessed by measuring pG5-luciferase activity. The data are from
a triplicate experiment and were normalized by Renilla luciferase activity. The values are shown ±SEMs. Signiﬁcance; *p < 0.001 vs. pACT-mock
control cells (Student’s t test). b Conﬁrmation of the interaction between ERK3 and FBXW7. The interaction of FBXW7 and ERK3 was conﬁrmed
by IP (HEK293T cell lysate, 400 μg/lane). c ERK3 interacted with cullin 1. The participation of ERK3 in a cullin 1 complex was conﬁrmed by IP
(HEK293T cell lysate, 400 μg/lane). d Speciﬁcity of the ERK3 binding of cullin members. Speciﬁc ERK3 binding with cullin members was
evaluated by IP. e ERK3 bound speciﬁcally to FBXW7 among FBXW subfamily members. Speciﬁc binding between ERK3 and FBXW subfamily
members was evaluated by IP. f Speciﬁc ERK3 binding with FBXW7 and FBXO subfamily members. Speciﬁc ERK3 binding with FBXW7 and
FBXO subfamily members was evaluated by IP. b–f β-Actin was used as the internal control to ensure equal protein loading. WCL, whole-cell
lysate.

using HEK293T cell lysates coexpressing HA-FBXW7 and MycERK3-1–721, Myc-ERK3-1–481, or Myc-ERK3-1–340 showed that
FBXW7 and ERK3 formed a complex in Myc-ERK3-1–721 and MycERK3-1–481 (Fig. 3a), suggesting that FBXW7 interacts with the
C34D of ERK. IP using Flag-FBXW7 and ERK3 mutants with serial
deletion from the N-terminus (Myc-ERK3-dN340) and amino acids
481–721 (Myc-ERK3-dN481) (Supplementary Fig. 2b) showed that
the C-terminal domain of ERK3 did not interact with FBXW7
(Fig. 3b). On the other hand, when we used FBXW7 serial deletion
mutants (Supplementary Fig. 2c), we observed that ERK3
interacted with full-length FBXW7 (Myc-FBXW7-1–707) but not
with the WD40 domain-deleted mutant (Myc-FBXW7-1–324) or
the WD40/F-box domain-deleted mutant (Myc-FBXW7-1–278)

(Fig. 3c). After determining the domain in ERK3 responsible for
the interaction with FBXW7, it was necessary to determine the
binding domain(s) of FBXW7. Based on the literature indicating
that Arg465, Arg479, and Arg505 of FBXW7 play a critical role in
the interaction of FBXW7 substrate25, we investigated the
interactions of FBXW7 mutants harboring R465H, R479L, or
R505C with ERK3. The IP results indicated that FBXW7 mutation
dramatically reduced the interaction with ERK3 (Fig. 3d). Notably,
when the ERK3 was coexpressed with each of FBXW7-wt or
-mutants, the decreased ERK3 protein levels were observed in
FBXW7-wt, but not in FBXW7-mutants (Fig. 3e). Cyclin E protein
levels also showed patterns similar to those of ERK3 levels,
indicating that ERK3 protein levels were regulated by interaction

Experimental & Molecular Medicine (2022) 54:35 – 46
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with the WD40 domain of FBXW7 (Fig. 3e). These results indicate
that the C34D of ERK3 interacts with the WD40 domain of FBXW7.
Thr417 and Thr421 of ERK3 act as degron motifs
To investigate the molecular mechanisms responsible for the
interaction between the C34D of ERK3 and the WD40 domain of
FBXW7, we ﬁrst tried to narrow down the region responsible for
ERK3 binding. IP using constructs with deletion of the C34D of ERK3

Experimental & Molecular Medicine (2022) 54:35 – 46

(Supplementary Fig. 3a) showed that Myc-ERK3-1–721 and MycERK3-1–481 immunoprecipitated with FBXW7, whereas Myc-ERK31–363 and Myc-ERK3-1–340 did not (Fig. 4a). These results support
the notion that the degron motif(s) of ERK3 spanning amino acids
364–481 are recognized by the WD40 domain of FBXW7.
Accordingly, we analyzed the sequence of ERK3 at amino acids
364–481 and found 5 putative degron motifs (PDMs), which were
designated PDMs 1–5 (Fig. 4b, maps). We ﬁrst constructed a
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Fig. 2 FBXW7 induced the ubiquitination of ERK3. a MG132 restored ERK3 protein levels. Lung cancer cells (H226 and H1299 cells) were
treated with MG132 (10 μM) for 4 h, and cell lysates (30 μg) were subjected to Western blotting to assess ERK3 protein levels. b FBXW7
downregulated ERK3 protein levels. FBXW7-mediated ERK3 protein level changes were assessed by Western blotting (30 μg protein/lane). c
Cullin 1 knockdown increased ERK3 protein levels. ERK3 protein levels in cullin-knockdown cells (30 μg protein/lane) were assessed by
Western blotting. d Upper panels, FBXW7 deﬁciency increased ERK3 protein levels. ERK3 protein levels in cell lysates (30 μg) of HCT116FBXW7+/+
and HCT116FBXW7−/− cells were determined by Western blotting. Cyclin E: positive control. Graphs, ERK3 gene expression was not involved in
ERK3 destabilization. ERK3 mRNA levels in HCT116FBXW7+/+ or HCT116FBXW7−/− cells were evaluated by real-time PCR. e FBXW7 attenuated
ERK3 degradation. Upper panels, ERK3 protein levels in HCT116FBXW7+/+ and HCT116FBXW7−/− cells were determined by Western blotting (30 μg
cell lysate/lane, CHX; 10 μg/ml). Graphs, The ERK3 band intensities were normalized to the β-actin intensity. f FBXW7 increased ERK3
ubiquitination. FBXW7-mediated ERK3 ubiquitination was evaluated by IP (400 μg cell lysate)/Western blotting. g Depletion of
FBXW7 suppressed ERK3 ubiquitination. Left panels, The endogenous ERK3 ubiquitination content in HCT116FBXW7+/+ and HCT116FBXW7−/−
cells was evaluated by IP (500 μg cell lysate/lane)/Western blotting. Graphs, The intensities of HA-Ubi ERK3 bands were measured and
normalized using ImageJ (ver. 1.52a). h Upper panels, FBXW7 knockdown attenuated ERK3 degradation. The ERK3 turnover rate in FBXW7knockdown A549 cells was evaluated by Western blotting (20 μg cell lysate/lane, CHX; 10 μg/ml). The ERK3 band intensities were normalized
to the β-actin intensity. Cyclin E, positive control. i FBXW7 reintroduction into FBXW7-knockdown cells suppressed ERK3 protein levels. The
ERK3 protein levels in A549 stable cells stably expressing sh-mock, sh-FBXW7, or sh-FBXW7/Lenti-pCDH-FBXW7 were determined by Western
blotting (20 μg cell lysate/lane). j Left panels, FBXW7 knockdown decreased the ERK3 turnover rate, which was increased by FBXW7
overexpression. The ERK3 turnover rate in A549 cells stably expressing Lenti-pCDH-FBXW7 or Lenti-pCDH-FBXW7/sh-FBXW7 was determined
by Western blotting (20 μg cell lysate/lane, CHX; 10 μg/ml). Graphs, The ERK3 band intensities were normalized to the β-actin intensity.
a-j β-Actin was used as the internal control to ensure equal protein loading. a-j The data are from three independent experiments. d, e, g, h, j
The values are shown ± the SEMs. Signiﬁcance; *p < 0.05, **p < 0.01 vs. indicated control by Student’s t test. f, g WCL, whole-cell lysate.

mutated expression vector of full-length ERK3 harboring a mutation
of Ser386/Thr389 to alanine at PDM1 (Myc-ERK3-FL-mtPDM1)
(Fig. 4b, bottom sequence alignment). IP using cell lysates transiently
expressing HA-FBXW7, HA-FBXW7/Myc-ERK3-FL-wt, or HA-FBXW7/
Myc-ERK3-FL-mtPDM1 showed that this PDM1 mutation did not
alter the interaction between FBXW7 and ERK3 (Fig. 4c). These
results indicate that PDM1 is not a degron motif of ERK3 for FBXW7.
Next, we constructed four independent expression vectors harboring a double mutation from PDM2 to PDM5. These vectors were
designated Myc-ERK3-FL-T417A/T421A, Myc-ERK3-FL-mtPDM2; MycERK3-FL-S428A/E432A, Myc-ERK3-FL-mtPDM3; Myc-ERK3-FL-T448A/
S452A, Myc-ERK3-FL-mtPDM4; and Myc-ERK3-FL-S477A/E481A, MycERK3-FL-mtPDM5 (Fig. 4d). IP results obtained using HA-FBXW7 and
these expression vectors showed that mutation of ERK3 Thr417 and
Thr421 to alanine (Myc-ERK3-FL-mtPDM2) dramatically reduced its
interaction with FBXW7 (Fig. 4e), whereas Myc-ERK3-FL-mtPDM3,
Myc-ERK3-FL-mtPDM4, and Myc-ERK3-FL-mtPDM5 had little effect
(Fig. 4e). Importantly, the reduction rate of the Myc-ERK3-FLmtPDM2 protein was lower after CHX treatment than the reduction
rate for the ERK3-wt (Fig. 4f and Supplementary Fig. 3b). To
determine whether the lower reduction rate of Myc-ERK3-FLmtPDM2 protein was due to the suppression of ubiquitination, we
conducted an FBXW7-mediated ERK3 ubiquitination experiment. As
expected, the ERK3 ubiquitination content was markedly lower for
Myc-ERK3-FL-mtPDM2 than for ERK3-wt (Fig. 4g). Notably, ex vivo
binding of FBXW7 and Myc-ERK3-wt or Myc-ERK3-mtPDM2 demonstrated that mutation of ERK3 at PDM2 suppressed the interaction
with FBXW7 (Fig. 4h). Furthermore, an in vitro ubiquitination
experiment demonstrated that mutations at PDM2 of ERK3
prevented FBXW7-mediated ERK3 ubiquitination (Fig. 4i). These
results demonstrated that the ubiquitination reduction in Myc-ERK3mtPDM2 was due to disruption of the ERK3-FBXW7 interaction.
These results show that FBXW7 modulates ERK3 stability by
interacting with Thr417 and Thr421 in the C34D of ERK3 using its
WD40 domain via a ubiquitination-mediated proteasomal degradation pathway.
The FBXW7-ERK3 signaling axis regulated the proliferation of
lung cancer cells
To examine the roles of ERK3-mediated cancer cell proliferation,
we knocked down ERK3 in H1299 and A549 lung cancer cells
(Supplementary Fig. 4a). Using these cells, we conﬁrmed that
although the inhibitory rates were different for each ERK3knockdown construct, the inhibitory patterns showed that ERK3
knockdown severely reduced cancer cell proliferation (Supplementary Fig. 4b). Notably, ERK3 knockdown resulted in the

formation of substantially fewer foci in A549 cells than sh-mock
treatment in control cells (Supplementary Fig. 4c). Since sh-ERK3#3 showed average inhibition of cell proliferation (Supplementary
Fig. 4b), we selected sh-ERK3-#3 for further analysis of ERK3’s role
in cancer cell proliferation. In addition, knockdown of ERK3 in both
cell lines induced cell growth arrest and signiﬁcantly reduced
focus formation (Fig. 5a, Supplementary Fig. 4d). Interestingly, we
found that ERK3 knockdown decreased CDK2 and cyclin A protein
levels and increased p21WAF1/Cip1 protein levels (Fig. 5b), indicating
that the ERK3 protein might play a role in cell cycle regulation.
Notably, ERK3-mtPDM2 overexpression increased the CDK2, CDK4,
and cyclin A protein levels (Fig. 5c). These results indicated that
ERK3 might be involved in the induction of cell proliferation. Since
ectopic expression of FBXW7 has been shown to suppress cell
proliferation25, ectopic expression of ERK3 or ERK3-mtPDM2 might
restore FBXW7-mediated inhibition of cell proliferation. As
expected, overexpression of FBXW7 decreased focus formation
(Fig. 5d, Lane 1 vs. 2). The reduction in focus formation was
somewhat attenuated by overexpression of ERK3-wt or ERK3mtPDM2 (Fig. 5d, Lane 2 vs. 3 or 4). The restoration ratio of focus
formation was higher in ERK3-mtPDM2-overexpressing cells than
in ERK3-wt cells (Fig. 5d, Lane 3 vs. 4). However, the restored focus
formation did not exceed the levels of the mock control cells
(Fig. 5d, Lanes 1 vs. 3 and 4). These results indicated that ERK3
might play a positive role in cell proliferation and focus formation.
To clarify the role of ERK3 in cell proliferation, we analyzed the
effect of ERK3 on cell cycle distribution by using hydroxyurea (HU)
to synchronize cells at the G1 phase of the cell cycle and releasing
ERK3 from G1 arrest by moving the cells to HU-free complete
medium to initiate DNA replication. Flow cytometry indicated that
mock-expressing stable cells showed an ~52% reduction in the
G1-phase cell cycle population and an ~51% increase in
the S-phase cell cycle population at the 12 h time point (Fig. 5e).
We observed that the ectopic expression of ERK3-wt suppressed
the G1-phase cell cycle population by approximately 26% and
increased the S-phase cell population by approximately 24% at
the 12 h time point (Fig. 5e). Compared to ERK3-wt overexpression, ERK3-mtPDM2 overexpression also resulted in a similar
increase and decrease in the cell cycle populations at the 12 h
time point (Fig. 5e). Importantly, the HU-induced 80% G1
accumulation in mock-overexpressing cells was reduced to
approximately 60–65% by ERK3-wt or ERK3-mtPDM2 overexpression (Fig. 5e). In contrast to the G1 population, the HU-treated 18%
S-phase cell cycle population in mock-overexpressing cells was
reduced to approximately 38–40% by ERK3-wt or ERK3-mtPDM2
overexpression (Fig. 5e). These results suggested that ERK3 acted
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Fig. 3 The C34D of ERK3 interacted with the WD40 domain of FBXW7. a Identiﬁcation of ERK3 domains that interact with FBXW7. The ERK3
domains interacting with FBXW7 were determined by IP (HEK293T cell lysate, 300 μg cell lysate/lane) and Western blotting. b Involvement of
the ERK3 C34D in its interaction with FBXW7. The ERK3 C34D was determined to interact with FBXW7 by IP (HEK293T cell lysate, 300 μg)/
Western blotting. c Determination of FBXW7 domains that interact with ERK3. The FBXW7 interaction domains interacting with ERK3 were
determined by IP (HEK293T cell lysate, 300 μg) and Western blotting. d Upper panels, Conﬁrmation that the WD40 domain interacts with ERK3.
The interactions of FBXW7 proteins containing each mutation in the WD40 domain and ERK3 were determined by IP and Western blotting
(MG132; 10 μM, 4 h). Graphs, Immunoprecipitated FBXW7 protein levels were normalized to the levels of immunoprecipitated Myc-ERK3. e
Upper panels, ERK3 protein levels were sustained in FBXW7 mutants. The ERK3 protein levels in HEK293T cells transiently expressing ERK3 and
each FBXW7 mutation as indicated were determined by Western blotting (CHX; 10 μg/ml, 1 h). Graphs, The Myc-ERK3 band intensities were
normalized to the β-actin intensity. a–e β-Actin was used as the internal control to ensure equal protein loading. WCL, whole-cell lysate.

as a positive regulator to enhance the rapid progression of the cell
cycle from G1 phase to the S phase. This hypothesis was
supported by monitoring the protein levels of cell cycle regulators,
including the CDK2, CDK4, cyclin E, E2F1, and phosphoretinoblastoma (Rb) proteins (Fig. 5f, g). The results indicated that
ERK3-wt protein levels decreased gradually by 16 h after HU
release and were increased at 17 h after HU release (Fig. 5f, top
Experimental & Molecular Medicine (2022) 54:35 – 46

panel, and g left-top). Interestingly, ERK3-mtPDM2 protein levels
were sustained and even increased in a time course after HU
release (Fig. 5f, top panel, and g left-top). Importantly, although
CDK4 and p21WAF1/Cip1 protein levels were not signiﬁcantly
changed (Fig. 5f, 6th–7th panels from top), cyclin E, CDK2, E2F1,
and phospho-Rb protein levels were increased in ERK3-mtPDM2overexpressing A549 cells in a time course after HU release
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compared to the levels in ERK3-wt-overexpressing A549 cells (Fig.
5f, g). Taken together, these results indicate that ERK3 plays an
important role in the G1/S-transition cell cycle checkpoint.
DISCUSSION
In the present study, our data showed that FBXW7 overexpression
inhibited focus formation in A549 cells more than ERK3 overexpression (Fig. 5d). Interestingly, ERK3 and FBXW7 coexpression
slightly restored focus formation, which was suppressed by FBXW7

alone (Fig. 5d). The restoration rate of focus formation was
signiﬁcantly increased by coexpression of ERK3-mtPDM2 and
FBXW7 (Fig. 5d). These results suggest that ERK3 has the potential
to enhance cell proliferation and focus formation. However, the
expression of ERK3-wt or ERK3-mtPDM2 was not fully restored or
increased compared to that in mock-expressing control cells
(Fig. 5d). However, we did not observe any cell death due to ERK3
overexpression. These results suggest that ERK3 might play an
important role when cells are situated in some conditions that are
not yet known. On the other hand, knockdown of ERK3 severely
Experimental & Molecular Medicine (2022) 54:35 – 46
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Fig. 4 Thr417/Thr421 of ERK3 acts as a degron motif to bind FBXW7. a The ERK3 C34D-364–481 region interacted with FBXW7. The
interaction of amino acids 364–481 of the ERK3 C34D with FBXW7 was determined by IP (HEK293T cell lysate, 300 μg/lane)/Western blotting. b
Upper panels, Vector maps indicating the locations of putative degron motifs (PDMs) for FBXW7 in the ERK3 C34D. Bottom panels, Amino acid
alignment of PDM1. c Ser386/Thr389 did not serve as an ERK3 degron for FBXW7. Ser386/Thr389 involvement in ERK3-FBXW7 binding was
determined by IP (HEK293T cell lysate, 300 μg/lane)/Western blotting. d Amino acid alignments and the locations of PDM2-5 of ERK3 in the
C34D. e Interaction between FBXW7 and ERK3-mtPDM2-5 mutants. The interaction of FBXW7 and each Myc-ERK3-FL-mtPDM was evaluated by
IP (HEK293T cell lysate, 300 μg)/Western blotting. f Upper panels, ERK3-mtPDM2 attenuated protein degradation. The turnover of ERK3 in A549
cells stably expressing ERK3-wt and ERK3-mtPDM2 was determined by Western blotting (CHX; 10 μg/ml). Graphs, The ERK3 band intensities
were normalized to the β-actin intensity. The data were obtained from three independent experiments. The values are shown with ±SEMs.
Signiﬁcance; **p < 0.05 vs. wt control by Student’s t test. g Myc-ERK3-FL-mtPDM2 reduced FBXW7-mediated ubiquitination. FBXW7-mediated
ERK3-FL and ERK3-FL-mtPDM2 ubiquitination was compared by IP (HEK293T cell lysate, 300 μg/lane)/Western blotting. h ERK3-mtPDM2
decreased complex formation with FBXW7 ex vivo. Immunopuriﬁed Flag-FBXW7 proteins were subjected to complex formation assays with
Myc-Ab-myc-ERK3-WT or Myc-Ab-myc-ERK3-mtPDM2 beads. The beads were washed, and ERK3 binding was determined by Western blotting.
The input was used to compare the protein amounts for these reactions. i FBXW7 ubiquitinated ERK3 in vitro. The proteins prepared in (h)
were subjected to conﬁrmation of the ERK3 ubiquitination degree using an in vitro ubiquitination kit as described in the Materials and
Methods. Ubiquitinated ERK3 protein levels were determined by Western blotting. a, c, e–g β-Actin was used as an internal control to ensure
equal protein loading. WCL, whole-cell lysate.

suppressed H1299 and A549 cell proliferation and eventually
caused proliferation arrest (Supplementary Fig. 4b–d). These
results also suggest some speciﬁc role of ERK3 in the determination of cell fate under particular conditions. This idea is supported
by the discovery that the activating phosphorylation of ERK3/ERK4
is not modulated by classic MAPK stimuli or by any other
extracellular stimuli examined26. Interestingly, ERK3 is present in
some snRNP-containing structural constituents, especially in
perichromatin ﬁbrils, where transcriptional and cotranscriptional
splicing of mRNAs occur27. Moreover, the interaction of ERK with
cyclin D3 and MK5 suggests that ERK3’s function is linked to cell
cycle progression and differentiation28. However, the upstream
stimuli and kinases directing ERK3 activation and subcellular
localization have not been clearly elucidated thus far.
ERK3-deﬁcient C57BL/6 mice are nonviable and show pulmonary hypoplasia and incomplete type II pneumocyte differentiation29. However, these observations were recently re-evaluated in
two publications that conﬁrmed that the observed phenotype is
likely attributable to off-target effects29–31. Our results conﬁrm
that ERK3 protein levels are positively correlated with the G1/S cell
cycle transition in A549 lung cancer cells (Fig. 5e). Although the
nuclear substrates of ERK3 that trigger cellular responses are
unknown, ERK3 is required for the nuclear abundance of c-Jun
protein and the DNA-binding activity of AP-1, which consequently
regulates IL-8 and chemotaxis16. These results suggest that ERK3
may also be involved in cell proliferation. Since MK5 is a wellknown direct downstream kinase that is targeted by ERK3 and
since ERK3 activation upregulates MK532, the phenotypes
manifested by ERK3 or MK5 loss-of-function might be similar.
For example, the L290V substitution in ERK3 has been observed in
lung and skin cancer samples, and ERK3 mRNA levels in oral
cancer tissues were 5- to 8-fold higher than those in healthy
tissues in 90% of patients (n = 37/41)33,34. In another study,
peripheral blood cell analysis showed that ERK3 mRNA levels were
elevated in ~61% (n = 8/13) of oral squamous cell carcinoma
patients but undetectable or low in healthy individuals 74%, (n =
23/31)35. These results indicate that ERK3 might be involved in
cancer development.
To investigate the mechanism of ERK3-mediated cancer cell
proliferation, we used H1299 and A549 lung cancer cells. Since
ERK3 is classiﬁed as an atypical MAP kinase ubiquitously expressed
in human tissues and since H1299 and A549 cells carry mutations
in the same family of Ras proteins (N-Ras and K-Ras, respectively),
we hypothesized that these two cells may exhibit similar
responses to ERK3 protein levels or activity. Surprisingly, different
effects of knockdown of the ERK3 gene were observed
(Supplementary Fig. 4a, b). Thus, to avoid biases caused by the
knockdown effect of the single clone sh-RNA, several different
clones of sh-RNA were generally examined to determine whether
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similar patterns of phenotypes were observable. If the effects of
gene knockdown are shown to have similar patterns in several
different clones, the clones showing these results can be selected,
as indicated by our current results (Fig. 5a–g). Although our results
showed different inhibition rates of cell proliferation depending
on the clone, the similar patterns of cell proliferation inhibition
caused by ERK3 knockdown indicated that ERK3 might positively
regulate cell proliferation (Supplementary Fig. 4a, b). Moreover, we
found that FBXW7 acts as an ERK3 stability regulator. Since FBXW7
acts as a tumor suppressor by targeting oncogenes for degradation36, ERK3 ubiquitination, and degradation mediated by
FBXW7 support the oncogenic function of ERK3. However, a
recent study reported that although BRAF increases ERK3
transcription and stability, ERK3 expression in melanoma cells
suppresses cell growth37. Although the physiological role of the
ERK3 protein remains controversial, our results consistently
support the idea that FBXW7 acts as a tumor suppressor. Thus,
we believe that FBXW7-mediated ERK3 degradation suppresses
cancer cell proliferation. We initially thought that ERK3 might
accelerate cell cycle progression in cancer cells. However, this view
was contradicted by the results of the focus formation assays on
cells stably expressing FBXW7, ERK3-wt, and/or ERK3-mtPDM2 and
by the results of the HU pulse/chase experiments. Surprisingly, we
found that FBXW7 alone suppressed focus formation in A549 cells,
whereas ERK3-mtPDM2 restored the number of foci after FBXWmediated suppression (Fig. 5d and Supplementary Fig. 4e). In
addition, compared to the expression of FBXW7 alone, coexpression of FBXW7 and ERK3-wt did not signiﬁcantly restore focus
formation (Fig. 5d). These results indicate that although
ERK3 seemingly plays an important role in cancer cell proliferation,
the molecular mechanisms responsible for regulating ERK3
protein levels and activities are complex. Moreover, since ERK3
protein levels were gradually decreased in HCT116FBXW7−/− cells
(Fig. 2e) and FBXW7-knockdown A549 cells (Fig. 2h) and since
ERK3 bound with different cullins and FBXO subfamily members
(Fig. 1d, f), we conclude that there are other E3 ligases that
regulate ERK3 protein levels, resulting in different roles depending
on the cellular context.
The subcellular localization events of enzymes are rate-limiting
events in cellular processes and determine enzymes’ roles in
responses to diverse physiological conditions38. To interact with
binding partners, enzymes must respond to stimuli initiated by
speciﬁc signaling pathways. ERK3 is a serine/threonine kinase that
exhibits maximum activity at the time of production and has a
half-life of <30 min14. Thus, we believe that regulation of the
stability of ERK3 controls its activity. Mechanistic studies on ERK3
activity regulation have shown that ERK3/ERK4 heterodimer
formation is required for the activation of MK539 due to
phosphorylation at Thr18240 and that this results in the
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Fig. 5 S-phase checkpoint regulation by the FBXW7-ERK3 axis regulates focus formation in cancer cells. a ERK3 knockdown inhibited the
proliferation of lung cancer cells. The effects of ERK3 knockdown on the proliferation of H1299 and A549 cells were evaluated by a focus
formation assay. b ERK3 knockdown reduced the protein levels of G1/S-phase cell cycle regulators. The levels of cell cycle regulation-related
proteins were evaluated by Western blotting (ERK3-knockdown A549 cell lysate, 30 μg/lane). c Ectopic expression of ERK3 increased the
protein levels of G1/S-phase cell cycle regulators. The protein level changes of G1/S-phase cell cycle regulators caused by ectopic expression of
ERK3-wt or ERK3-mtPDM2 were evaluated by Western blotting (A549 cell lysate, 30 μg/lane). d Ectopic expression of ERK3-mtPDM2 reversed
the FBXW7-mediated inhibition of focus formation. A549 cells stably expressing mock, ERK3-wt, FBXW7, or ERK3-mtPDM2 were used to
investigate the role of the FBXW7-ERK3 axis in focus formation. e-g ERK3 induced the G1/S-phase cell cycle transition. The A549 cells in c were
synchronized at the G1 phase of the cell cycle by HU treatment (48 h) and then released via culture in a complete growth medium. At each
time point after HU release, ﬂow cytometry was used to analyze the cell cycle distribution (e), and Western blotting was used to conﬁrm the
protein oscillations (f). The graphs in g show the oscillation pattern of each indicated protein after HU release. The band intensities of each
indicated protein were normalized to the β-actin intensity. a, d The data were obtained from three independent experiments. The values are
shown ±SEMs. Signiﬁcance; *p < 0.05, **p < 0.01 vs. nontreated control or sh-mock by Student’s t test. b, c, f β-Actin was used as an internal
control to ensure equal protein loading.

translocation of ERK3 and ERK4 from the nucleus to the
cytoplasm32,40. Furthermore, FIH- or PHD3-dependent mechanisms have been suggested to underlie the ubiquitination of ERK3
induced by its hydroxylation41. Furthermore, studies have
suggested that among the enzymes that inhibit ERK3 hydroxylation, HUWE1 and UBE3A are closely related to ubiquitination, and

RAD23b and ECM29 are related to ubiquitin recognition and
proteasome degradation41. However, evidence regarding the
ubiquitination of ERK3 indicates that its deubiquitination by
ubiquitin-speciﬁc protease 20 (USP20) dose-dependently prolongs
its half-life42. These results strongly support our hypothesis that
ERK3 ubiquitination regulates ERK3 activity. However, no clear
Experimental & Molecular Medicine (2022) 54:35 – 46
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evidence has been published regarding the induction of ERK3
ubiquitination by E3 ligases. In the present study, FBXW7 was
found to be a novel binding partner of ERK3 (Fig. 1a), and
HCT116FBXW7−/− cells were found to contain higher ERK3 protein
levels than HCT116FBXW7+/+ cells (Fig. 2d). Notably, the ubiquitinated ERK3 protein levels were lower in HCT116FBXW7−/− cells than
in HCT116FBXW7+/+ cells (Fig. 2g). Thus, it appears that the FBXW7ERK3 signaling axis plays an important role in the regulation of
ERK3 activity in response to speciﬁc stimuli. However, the
signaling pathway upstream of ERK3 has yet to be elucidated.
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